Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06768294 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Baricitinib in CPPD - the BAPTIST Study

Study acronym: BAPTIST
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 10, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The aim of this clinical trial is to determine if baricitinib is effective in treating calcium pyrophosphate deposition disease (CPPD) in adults. The primary objective is to assess its impact on joint inflammation. The key questions the study seeks to answer are: * Can baricitinib reduce inflammation in affected joints? * Will baricitinib lead to changes in ultrasound findings, such as calcium crystal deposition and synovitis? Researchers will compare baricitinib to other treatments, including methylprednisolone, colchicine, hydroxychloroquine, and methotrexate with folic acid, for managing CPPD.
Trial Details
NCT Number NCT06768294
Lead Sponsor I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Conditions
(from sponsor)		 Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis
Related terms Arthritis, Chondrocalcinosis
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov